<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01702675</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-HML-01(03/12)</org_study_id>
    <nct_id>NCT01702675</nct_id>
  </id_info>
  <brief_title>Study to Assess Tolerability, Safety and Pharmacokinetics of a New Drug</brief_title>
  <acronym>ACH15</acronym>
  <official_title>Phase I, Monocentric, Double-blind, Randomized Study to Assess Tolerability, Safety and Pharmacokinetics of ACH15 After Single Dose and Multiple Doses in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ache Laboratorios Farmaceuticos S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is evaluate the safety and tolerability parameters regarding the
      new drug in healthy men and evaluate the pharmacokinetics parameters after one dose and
      multiple doses of the new drug.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Echocardiography (participants included in Group 6)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>31 time points up to 2 days</time_frame>
    <description>Blood analysis to evaluate drug pharmacokinetics at Group 1 to 5: 30 minutes and 05 minutes before dose and 00h10 min, 00h15 min, 00h30 min, 00h45 min, 01h, 01h15min, 01h30min, 01h45min, 02h, 02h15min, 02h30min, 02h45min, 03h, 03h15min, 03h30min, 03h45min, 04 h, 04h15min, 04h30min, 04h45min, 05h, 05h30min, 06 h, 08 h, 10 h, 12h, 16h, 24 h e 48hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High digestive endoscopy (participants included at Group 6)</measure>
    <time_frame>8 days</time_frame>
    <description>Image exam to evaluate the drug safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood analysis</measure>
    <time_frame>30 days</time_frame>
    <description>Blood will be collected to evaluate the drug safety by analysis of biochemical profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>67 pint time over 8 days</time_frame>
    <description>Blood analysis to evaluate drug pharmacokinetics at Group 6:00:30 min before dose, 00h20min, 00h40min, 01h, 01h15min, 01h30min, 01h45min, 02h, 02h15min, 02h30min, 02h45min, 03h, 03h15min, 03h30min, 03h45min, 04h, 04h15min, 04h30min, 04h45min, 05h, 05h30min, 06h, 08h, 10h, 12h, 14h, 18h, 24h, 26h, 30h, 36h, 38h, 42h, 48h, 50h, 54h, 60h, 62h, 66h, 72h, 74h, 78h, 84h, 86h, 90h, 96h, 98h, 102h, 108h, 110h, 114h, 120h, 122h, 126h, 132h, 134h, 138h, 144h, 146h, 150h, 156h, 158h, 162h, 168h, 174h, 180h e 192h post-dose.</description>
  </primary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ACH15 - 50mg capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACH15 50mg capsule by mouth single dose (Group 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACH15 - 250 mg capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACH15 250mg capsule by mouth as single dose(Group 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACH15 - 500mg capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACH15 500mg capsule by mouth in a single dose(Group 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACH15 - 1000 mg (two 500mg capsule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACH15 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACH15 - 2000 mg (four 500 mg capsule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACH15 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACH15 - 500 mg (twice a day for 7 days)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACH15 500mg capsule by mouth twice a day for seven days (Group 6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - 250 mg capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 250mg capsule by mouth single dose (Group 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - 500 mg capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 500mg capsule by mouth in a single dose(Group 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - 1000 mg (two 500mg capsule)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 2000 mg (four 500mg capsule)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - 500 mg (twice a day for 7 days)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 500mg capsule by mouth twice a day for seven days (Group 7)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH15 50 mg</intervention_name>
    <description>ACH15 50mg capsule</description>
    <arm_group_label>ACH15 - 50mg capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH15 250 mg</intervention_name>
    <description>ACH15 250mg capsule</description>
    <arm_group_label>ACH15 - 250 mg capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH15 500mg</intervention_name>
    <description>ACH15 500 mg capsule</description>
    <arm_group_label>ACH15 - 500mg capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH15 - 1000mg</intervention_name>
    <description>ACH15 500mg capsule - two 500mg capsules in single dose</description>
    <arm_group_label>ACH15 - 1000 mg (two 500mg capsule)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH15 - 2000mg</intervention_name>
    <description>ACH15 500mg capsule (four 500mg capsules in one dose)</description>
    <arm_group_label>ACH15 - 2000 mg (four 500 mg capsule)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH15 - 500mg</intervention_name>
    <description>ACH15 - 500mg twice a day for 7 days</description>
    <arm_group_label>ACH15 - 500 mg (twice a day for 7 days)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 250 mg</intervention_name>
    <description>Capsule manufactured to mimic ACH15 250 mg capsule</description>
    <arm_group_label>Placebo - 250 mg capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 500mg</intervention_name>
    <description>Capsule manufactured to mimic ACH15 500 mg capsule</description>
    <arm_group_label>Placebo - 500 mg capsule</arm_group_label>
    <arm_group_label>Placebo - 500 mg (twice a day for 7 days)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 1000mg</intervention_name>
    <description>Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (two 500 mg capsules in one dose)</description>
    <arm_group_label>Placebo - 1000 mg (two 500mg capsule)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 2000mg</intervention_name>
    <description>Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (four 500 mg capsules in one dose)</description>
    <arm_group_label>Placebo 2000 mg (four 500mg capsule)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 500mg</intervention_name>
    <description>Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (500 mg capsules twice a day for 7 days)</description>
    <arm_group_label>Placebo - 500 mg capsule</arm_group_label>
    <arm_group_label>Placebo - 500 mg (twice a day for 7 days)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patient, aged between 18 and 50 years;

          -  Body weight ≥ 50 kg and BMI ≥ 18.5 kg/m2 and ≤ 30 kg/m2;

          -  Healthy men accordance with their historical and tests;

          -  Healthy subject with laboratory results within the normal range or within the
             parameters accepted by the clinical protocol

          -  Negative results for parasitological stool examination performed in the clinical
             study;

          -  Subject of research with laboratory results within the normal range for urinalysis
             collected before the first visit;

          -  Research subjects allocated in Group 6 with endoscopy within the normal range;

        Exclusion Criteria:

          -  History of gastrointestinal disease, hepatic, renal, cardiovascular, pulmonary,
             neurologic, hematologic, diabetes or glaucoma;

          -  Evidence on clinical examination or physical or complement, organ dysfunction or any
             clinically significant deviation from normality;

          -  History of use of psychotropic drugs or excessive alcohol consumption (more than two
             units of alcohol per day, one unit being equivalent to one cup (200 mL) of brew or a
             dose (50) mL of distilled beverage) or having difficulty to abstain during the study;

          -  Use of any medication two (2) weeks prior to inclusion of the research subject in the
             study;

          -  Regular smokers or who quit less than one (1) year;

          -  History of food allergy or hyperreactivity to medications or foods;

          -  HIV positive for HIV;

          -  Being positive for Hepatitis B;

          -  Being positive for hepatitis C;

          -  Testing positive for Helicobacter pilorum;

          -  Using substances modulating hepatic microsomal activity within thirty (30) days prior
             to entry of the subject of research in the clinical study (date of signing the consent
             form);

          -  Having donated blood (blood volume higher than 500 mL) within four (4) months
             preceding the date of signing the consent form;

          -  Subject with a history of hypersensitivity to any component of the investigational
             product;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sérgio Vencio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICF - Instituto de Ciências Farmacêuticas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICF - Instituto de Ciências Farmacêuticas</name>
      <address>
        <city>Aparecida de Goiânia</city>
        <state>Goiás</state>
        <zip>74935-530</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2012</study_first_submitted>
  <study_first_submitted_qc>October 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2012</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Healthy men</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

